Keros Therapeutics Q1 EPS $(1.21) Beats $(1.34) Estimate, Sales $83.00K
Portfolio Pulse from Benzinga Newsdesk
Keros Therapeutics reported Q1 earnings with losses of $(1.21) per share, surpassing the analyst consensus estimate of $(1.34) by 9.7%. Year-over-year, this represents a 3.97% improvement in losses per share from $(1.26). The company also reported $83.00 thousand in sales for the quarter.
May 08, 2024 | 12:29 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Keros Therapeutics exceeded Q1 EPS estimates and showed a year-over-year improvement in losses, alongside reporting $83K in sales.
Beating EPS estimates and showing an improvement in losses compared to the previous year are positive indicators for investors. The reported sales, although modest, contribute to a positive outlook for KROS in the short term. These factors are likely to instill investor confidence and could lead to a positive impact on the stock price.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100